510(k) Report

510(k) · Cleared

Cleared

Elecsys Anti-SARS-CoV-2

K253839510(k) SpecialCleared Dec 17, 202516-day reviewClass II21 CFR 866.3983

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Roche Diagnostics · QVP Sars-Cov-2 Serology Test

Cleared on Dec 17, 2025 as substantially equivalent to K250768 (Roche Diagnostics, 2025) after a 16-day review. Its family tree reaches back 2 generations to 2023.

Decided
Dec 17, 2025
Review
16 days
Class
Class II
Product code
QVP
Recalls
None
Predicates
1

Its longest line of descent runs back 2 generations to DEN210040 (2023). No later device cites it as a predicate yet.

  1. Root · 2 generations backDEN210040 VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total Reagent Pack…Ortho-Clinical Diagnostics, Inc. · 2023
  2. 1 generation backK250768 Elecsys Anti-SARS-CoV-2Roche Diagnostics · 2025
  3. This deviceK253839 Elecsys Anti-SARS-CoV-2Roche Diagnostics · 2025
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−2DEN210040VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total Reagent Pack, VITROS…Ortho-Clinical Diagnostics, Inc.2023—
−1K250768Elecsys Anti-SARS-CoV-2Roche Diagnostics2025—
0 (this device)K253839Elecsys Anti-SARS-CoV-2Roche Diagnostics2025—
FIG. 1 — Lineage of K253839, 2023–2025Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in QVP? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new QVP device

  1. #1 K250768 Elecsys Anti-SARS-CoV-2score 12.5 · 1 generation · no Class I recall
  2. #2 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K250768Elecsys Anti-SARS-CoV-2
Summary page 7
…tended for use on cobas e 601 immunoassay analyzer. 3. TECHNOLOGICAL CHARACTERISTICS Technical characteristics comparison table between Elecsys Anti-SARS-CoV-2 (K250768) and Elecsys Anti-SARS-CoV-2 (K253839) Item Predicate, K250768 Candidate Device, K25…
Roche Diagnostics2025—

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 2 years and passes through 2 companies; a new generation was cleared every 2.1 years on median.
  • None of the 2 ancestors has a recall.

How does its category compare?

All QVP devices

QVP Sars-Cov-2 Serology Test: FDA decisions, review times, recalls and adverse event reports over 20 years. 2025, this device’s year, is highlighted.

FDA decisions per year · QVP

2in 2025

2023: 22025: 22026 (partial year): 1
2007high 2 (2023) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · QVP

Too few QVP 510(k)s in any year since 2007 to give a median.

Recalls per year · QVP

No recall names QVP since 2007.

Adverse event reports per year · QVP

No MAUDE report names QVP since 2007.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20080—00
20090—00
20100—00
20110—00
20120—00
20130—00
20140—00
20150—00
20160—00
20170—00
20180—00
20190—00
20200—00
20210—00
20220—00
20232—00
20240—00
20252—00
20261—0—

What is it indicated for?

Elecsys Anti-SARS-CoV-2 is an immunoassay intended for the in vitro qualitative detection of total antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in human serum and Li-heparin, K2-EDTA and K3-EDTA plasma collected on or after 15 days post-symptom onset. The test is intended as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection.

The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e 601 immunoassay analyzer.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K253839: Elecsys Anti-SARS-CoV-2.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K253839

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026